Table 4.

Treatment-related toxicities

Toxicities	Entire cohort (N = 43)
	Grade 1	Grade 2	Grade 3
Dermatitis	28 (65.1%)	14 (32.6%)	1 (2.3%)
Mucositis	13 (30.2%)	18 (41.9%)	9 (20.9%)
Dry mouth	14 (32.6%)	29 (67.4%)	0
Leucopenia	13 (30.2%)	14 (32.6%)	6 (14.0%)
Anemia	11 (25.6%)	2 (4.7%)	0
Thromboembolic events	0	1 (2.3%)	0
Hepatic dysfunction	8 (18.6%)	3 (7.0%)	2 (4.7%)
Nephrotoxicity	2 (4.7%)	0	0
Fatigue	28 (65.1%)	7 (16.3%)	1 (2.3%)
Loss of appetite	18 (41.9%)	10 (23.3%)	2 (4.7%)
Diarrhea	1 (2.3%)	0	0

Data are n (%). No grade 4 or 5 adverse event was observed